Three commercially available assays (the Varicelisa Test Kit [Whittaker M.A. Bioproducts, Walkersville, Md.], the VZV Indirect Fluorescent-Antibody Test [Electro-Nucleonics, Inc., Columbia, Md.], and the Litton VZV Bio-EnzaBead Screen Kit [Litton Bionetics, Inc., Charleston, S.C.]) and two enzyme-linked immunosorbent assays used in our laboratory, one using a membrane-associated antigen and the other using a soluble antigen dotted on nitrocellulose paper, were compared with a varicella-zoster virus antibody reference assay, the fluorescent-antibody-to-membrane-antigen test. All of the assays compared favorably to the fluorescentantibody-to-membrane-antigen test when evaluated for sensitivity (0.95), specificity (0.84), and test-retest reliability (79 to 96%), except for the Litton assay, which demonstrated significantly different results for all of the parameters tested (0.55, 1.0, and 69%, respectively).
The presence of serum antibody to varicella-zoster virus (VZV) has been shown to correlate with immunity to varicella (6, 15) . Determination of immune status to varicella is of vital importance in the containment of nosocomial infection and in deciding whether to administer postexposure prophylaxis with varicello-zoster immune globulin (VZIG) (1, 3) . It will be important in determining the eligibility of some patients for live attenuated VZV vaccine when it becomes licensed.
In a previous study, we have shown that the prevalence of immunity to VZV in a sample of normal adults with no history of varicella was 0.76 (10) . Therefore, using only history of clinical disease as an indicator of immunity to VZV is an insensitive and ultimately costly method in people with no history of varicella (9) . Until recently, assays for antibody to VZV have only been available in a few reference laboratories using the fluorescent-antibody-to-membraneantigen test (FAMA), a radioimmune assay, or an enzymelinked immunosorbent assay (ELISA). A number of commercial VZV antibody kits are now available. We evaluated three of the commercial kits and two ELISAs currently in use in our laboratory, comparing the sensitivity, specificity, and test-retest reliability with those of the FAMA, which has been the standard for determining immunity to VZV in our laboratory (15) .
MATERIALS AND METHODS
Serum samples were collected from 229 consecutive subjects (mean age, 32 ± 11.8 years), most (220/229) of whom could not recall having had varicella. A subset (n = 24) of the sample was selected, by using a random-number table, for repeat testing to evaluate test-retest reliability.
The important features of all of the assays are outlined in Table 2 also shows the sensitivity and specificity of the individual assays as compared with the FAMA. By definition, the sensitivity and specificity of the FAMA are 1.0. The sensitivity of an assay was defined as the proportion of FAMA-positive sera which were positive in that assay, and the specificity was defined as the proportion of FAMAnegative sera which were negative in that assay. The sensitivity (0.95) and specificity (0.84) were similar for all of the assays except the Litton assay (sensitivity, 0.55; specificity, 1.0). Figure 1 shows the predictive value (PV) of a positive test. Plotted on the x axis is the prevalence of immunity to VZV in a population (0 to 1.0). Plotted on the y axis is the probability of immunity to VZV given a positive test result (0 to 1.0). The values for the M-ELISA and the MAB assay were similar and resulted in superimposed curves. If the prevalence of immunity to VZV in the population studied (normal adults with no history of varicella) is estimated to be 0.76, that is, the proportion of sera positive in the FAMA assay, then a positive result in any assay but the Litton assay increases the probability of immunity from 0.76 to 0.95. A positive result in the Litton assay improved the probability of immunity to 1.0. Figure 2 shows the PV of a negative test. Plotted on the x axis is the prevalence of immunity to VZV, and on the y axis is the probability of susceptibility given a negative test result. If the prevalence of immunity in the population of normal adults with no history of varicella is estimated to be 0.76, then a negative result in any of the assays except the Litton assay increases the probability of susceptibility from 0.24 (i.e., 1 -the prevalence of immunity) to 0.84. A negative result in the Litton assay increased the probability of susceptibility from 0.24 to 0.45. Table 3 shows the proportion of correct answers for each assay, defined as the proportion of test results for each assay that agreed with the result of the FAMA. When analyzed by the chi-square test, the D-ELISA, MAB assay, ENI assay, and M-ELISA formed a homogeneous group (P = 2.3), indicating no significant difference among the results of these assays. When the results of the Litton assay were included, the group became heterogeneous, indicating that there was a significant difference between the results of the Litton assay and those of the other four assays (P < 0.001). In the subset of 135 sera for which all six assays were performed, there was agreement among all six assays for 79 sera (59%), among five of the six assays for 39 sera (29%), among four of the six assays for 14 sera (10%), and among three of the six assays for three sera (2%). In the group of 39 sera for which there was agreement among five of the six assays, the discordant assay was the Litton assay in 32 cases, the MAB assay in 3 cases, the M-ELISA in 2 cases, and the ENI assay and the FAMA in 1 case each. In the group of 14 sera for which there was agreement in four of the six assays (i.e., 28 discordant results), the discordant assay was the Litton assay in 11 cases, the ENI assay in 7 cases, the FAMA in 5 cases, the MAB assay and the D-ELISA in 2 cases each, and the M-ELISA in 1 case. Table 4 shows the test-retest reliability for the sample of sera randomly selected to be retested. Limited availability of the Litton assay kits allowed retesting of only 13 of the 24 randomly selected sera. Agreement for test and retest ranged from 100% (FAMA) to 69% (Litton assay). By the type of analysis described above, when the results of the Litton assay were added to the results of the homogeneous group consisting of the other five assays, the group became heterogeneous. (P = 0.03), indicating a significant difference between the test-retest results of the Litton assay and those of the others.
DISCUSSION
The prevalence of immunity to VZV in our sample of subjects with no history of varicella was 0.76 (Table 1) . This is in agreement with previous studies (4, 5, 7, 13) . Other authors have reported both higher (0.95) and loWer (0.47) prevalences in similar populations (11, 12) ; This variation in the prevalence of immunity may be a reflection of the mean age of adults, the proportion of people from tropical countries (see below), and the sensitivities of the assays used in the different studies.
To come to a conclusion on the usefulness the various assays, one must first define the population to be studied. In (14) . The utility of the assays in this situation is similar to that described above for the history-negative group from a temperate climate.
In our study, all of the assays except the Litton assay performed comparably when measured against the FAMA. We found the Litton assay to be highly specific but relatively insensitive. In addition, it had the lowest test-retest reliabil- 
